At the news
? BULLISHIMPACT 7/10 8-K filed May 8, 2026 at 09:10 ET
BioAge Labs reported Q1 2026 collaboration revenue of $2.8M (up from $1.5M YoY) and an EPS beat of $-0.52 vs consensus $-0.71 (26.8% beat). Net loss widened to $22.3M from $12.9M, driven by increased R&D spending on BGE-102 and APJ programs. The company highlighted positive Phase 1 data for BGE-102 and plans to initiate Phase 2 trials in mid-2026, with a strong cash position of $384.9M.
- Collaboration revenue of $2.8 million in Q1 2026 vs $1.5 million in Q1 2025
- Net loss of $22.3 million ($0.52 per share) vs consensus estimates of $-0.71 per share
- Positive topline Phase 1 data for BGE-102 (oral NLRP3 inhibitor) showing 86% median hsCRP reduction
- Phase 2 dose-ranging trial in cardiovascular risk planned for mid-2026, data expected by year-end
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access